This article is more than 5 years old. Information may no longer be current.
Oraya Therapeutics completes enrollment in wet
AMD trial
Click Here to Manage Email Alerts
NEWARK, Calif. — Oraya Therapeutics has completed enrollment in a clinical trial to determine the safety and efficacy of radiation therapy with anti-VEGF injections for the treatment of wet age-related macular degeneration, according to a company press release.
The INTREPID trial, which will be conducted in Europe, is the first sham-controlled, double-masked study to analyze combination radiation therapy for wet AMD.
Oraya enrolled 226 subjects to receive its proprietary IRay stereotactic radiotherapy treatment, a one-time, nonsurgical procedure that could reduce or eliminate the need for subsequent anti-VEGF injections, the release said.
One-third of the subjects will receive sham treatment, and the remainder will receive a radiation dose of 16 Gy or 24 Gy.
One-year efficacy results will be available in the second quarter of 2012. A larger trial is planned for later this year because the company could not accommodate all of the patients who showed interest in the trial, according to the release.